Beremagene geperpavec · Vyjuvek

Gene therapy / editing

Approvedregulatory verdict

Evidence outlook

Approved: Dystrophic Epidermolysis Bullosa

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (3)
UK
  • Wounds in patients with dystrophic epidermolysis bullosa
Product first approved 2026finviz.com
JP
  • Dystrophic epidermolysis bullosa (wounds), from birth
Product first approved 2025biospace.com
EU
  • Wounds in patients with dystrophic epidermolysis bullosa with COL7A1 mutations, from birth
Product first approved 2025pharmanow.live

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Dystrophic Epidermolysis Bullosa
Phase 1/2 (1)
Dystrophic Epidermolysis Bullosa
NCT03536143 · Krystal Biotech, Inc.
2018-05-06 – 2019-11-01 · Dystrophic Epidermolysis Bullosa
What this study did

Competitive landscape

This drug's own stage for Dystrophic Epidermolysis Bullosa: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Beremagene Geperpavec (Vyjuvek): this drugApprovedGene therapy / editingCOL7A1 (type VII collagen gene replacement)Partial signal
NCT04491604: Primary Wound With Complete Wound Healing (100% Wound Closure) on Weeks 22 and 24 or Weeks 24 and 26 (26 weeks post-baseline): B-VEC 20.9 number of wounds with complete healing | Placebo 6.7 number of wounds with complete healing
ALLO-ASCPhase 2Cell therapyAdipose-derived MSC therapynot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

15 May 2026ApprovalMHRA grants UK marketing authorization for VYJUVEK
UK, MHRA · Source ↗
24 July 2025ApprovalVYJUVEK approved in Japan for DEB
JP, MHLW · Source ↗